Which probiotic strains have real evidence for diarrhea and IBS?

Probiotic benefits are strain-specific, meaning results from one strain cannot be generalized to others even within the same species. Here are the best-supported strains for common conditions:

Antibiotic-associated diarrhea: Saccharomyces boulardii (a beneficial yeast, not a bacterium) has the strongest evidence for preventing diarrhea caused by antibiotics, including Clostridium difficile infection. A Cochrane review found that probiotics reduced the risk of C. difficile-associated diarrhea by about 60% when given alongside antibiotics¹. Lactobacillus rhamnosus GG is another well-supported strain for this use².

Irritable bowel syndrome (IBS): Bifidobacterium longum 35624 (also marketed as Bifidobacterium infantis 35624) has shown the ability to reduce bloating, abdominal pain, and bowel irregularity in IBS patients. Importantly, it also normalized the ratio of anti-inflammatory to pro-inflammatory cytokines, suggesting a genuine immunomodulatory mechanism rather than just symptom masking⁵.

Acute infectious diarrhea: A Cochrane meta-analysis of 63 trials, 56 of them in infants and young children, found that probiotics reduced the mean duration of acute infectious diarrhea by roughly one day (24.76 hours), although the size of the effect varied considerably between studies and was not explained by the probiotic strain².

Multi-strain formulations: Some conditions may respond better to combinations of strains. Francavilla et al. (2019) showed that a multispecies probiotic improved persistent GI symptoms in celiac patients already on a gluten-free diet, where single-strain approaches had been less effective⁴.

The Cochrane review by Goldenberg et al. analyzed 31 randomized controlled trials (8,672 participants) examining probiotics for C. difficile-associated diarrhea. The pooled analysis showed a significant risk reduction (RR 0.40, 95% CI 0.30 to 0.52) for C. difficile-associated diarrhea when probiotics were co-administered with antibiotics. S. boulardii and L. rhamnosus GG were the most frequently studied strains with positive outcomes. The number needed to treat was 33 for moderate-risk populations and 12 for high-risk populations¹.

Allen et al. (2010) conducted a Cochrane meta-analysis of 63 trials covering 8,014 participants examining probiotics for acute infectious diarrhea; 56 of the trials recruited infants and young children. Probiotics reduced the mean duration of diarrhea by 24.76 hours (95% CI 15.9 to 33.6 hours; 35 trials, 4,555 participants), although the size of the effect varied considerably between studies. The differences in effect size were not explained by study quality, probiotic strain, dosage of organisms, or the cause or severity of the diarrhea, and the authors concluded that more research is needed to guide the use of particular probiotic regimens in specific patient groups².

McFarland (2010) reviewed the evidence for Saccharomyces boulardii across multiple gastrointestinal indications. This probiotic yeast is notable because it is naturally resistant to antibiotics, making it particularly suitable for use during antibiotic therapy. The review found positive evidence for prevention of antibiotic-associated diarrhea (RR 0.47, 95% CI 0.35 to 0.63), traveler's diarrhea, and recurrent C. difficile infection. S. boulardii exerts its effects through multiple mechanisms including secretion of a protease that degrades C. difficile toxin A and stimulation of secretory IgA³.

O'Mahony et al. (2005) conducted a randomized controlled trial comparing B. longum 35624, L. salivarius UCC4331, and placebo in IBS patients over 8 weeks. Only B. longum 35624 significantly reduced composite IBS symptom scores. Critically, this strain also normalized the IL-10/IL-12 cytokine ratio, which was abnormally skewed toward the pro-inflammatory IL-12 at baseline. This finding provided mechanistic evidence that certain probiotic strains can modulate systemic immune responses, not just local gut effects⁵.

Francavilla et al. (2019) studied 109 celiac patients with persistent IBS-type symptoms despite adherence to a gluten-free diet. A 6-week course of a multispecies probiotic (containing Lactobacillus and Bifidobacterium strains) significantly reduced IBS Severity Scoring System scores and was associated with shifts in fecal microbiota composition, including increased Bifidobacterium counts. This study is notable because it demonstrates probiotic efficacy in a population where residual gut dysbiosis persists despite dietary treatment of the primary condition⁴.